Northstar Project & Real Estate Services’ Post

In Case You Missed It: The "Understanding Digital Therapeutics" webinar on Tuesday helped us all gain insights into the dynamic digital therapeutics industry directly from leading experts! DTA would like to thank: - Jeffrey Abraham, Partner Health Advances - Barbara Heikens, Vice-President, Commercial MedRhythms, Inc. - Jonathan Hodgson, Managing Director ClearView Healthcare Partners - Brandon Wade, Vice President Health Advances - Benjamin Alouf MD, MBA And DTA's very own Andy Molnar, who shared the foundational understanding and aspirations of DTx. Stay tuned for more #digitalhealthtechnology webinars from the #DTACommunity!

Thank you, Needham & Company, for the opportunity to share our story with the executives, leaders, and investors who attended the 23rd Annual Needham Virtual Healthcare Conference.    Our CEO, Dave Marver, gave a presentation on progress towards our 2024 strategic objectives. Our highlights so far this year include:   ⭐️ Our recent De Novo medical device application to the US Food & Drug Administration (FDA) for our first-of-its-kind investigational ARC-EX® System designed to restore upper limb function after spinal cord injury (SCI).   ⭐️ Acceptance into the US FDA’s new Total Product Lifecycle Advisory Program (TAP), which provides us with streamlined US regulatory review for our investigational ARC-BCI™ System. We are the second brain-computer interface (BCI) company to be accepted into this prestigious program.   ⭐️ We received our tenth Breakthrough Device Designation (BDD) from the US FDA for our ARC-BCI System based on clinical data from two human feasibility studies. This makes us the FIRST company in the world to receive breakthrough designation for a BCI paired with therapeutic stimulation. ⭐️ Our successful EUR 20M capital raise, led by EQT Life Sciences, Inkef, our CEO Dave Marver, and several members of our Board of Directors and Management Team.    We appreciate the opportunity to collaborate with digital health leaders and investors dedicated to supporting innovative solutions for the SCI Community.   *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.   #EmpoweringMovement #SCI #Innovation

A snippet of our conversation about #myeloma with the International Myeloma Foundation…

At Melinta Therapeutics, our commitment is to provide innovative therapies to people impacted by acute and life-threatening illnesses. Our vision is that all people who need our therapies will receive them. During the recent NewYorkBIO Life Science Showcase at NYSE, I had the privilege of presenting our mission and highlighting Melinta's remarkable evolution over the past few years, positioning us as an exceptional platform for growth. This year, with a team of 145 dedicated employees and a global presence in 105 markets, we are achieving meaningful growth. But beyond these impressive figures, our focus remains on revolutionizing acute care delivery. Throughout our journey of growth and transformation, we’ve remained steadfast in our commitment to improving patient outcomes. The landscape of acute care is intricate and dynamic, with substantial challenges in launching and commercializing new therapies, coupled with a pressing clinical need for innovative solutions. Nevertheless, this past year has given me more hope than ever that positive changes are not only possible, but already happening. I have only to look at the extraordinary work Melinta has done in this space to prove it…and we’re just getting started. Thank you again to NewYorkBio Life Science Showcase for providing a platform to share Melinta’s vision and strategic direction. I can’t wait to see where next year takes us! #InnovativeTherapies #HealthcareTransformation #GlobalImpact #MelintaMilestones

"Hey Kristin, what do you think the blind community really needs?" Jamie Ring dropped this game-changing question way back when she was working with Spark Therapeutics, Inc. to shake up the world of inherited retinal diseases with their groundbreaking treatment, Luxturna. And you know what? No one had ever asked me that before. Can you believe it? I've shared this story and the impact with so many of you in the pharmaceutical, rare disease and clinical research communities, on your stages and in within your organizations. Jamie's passion for truly understanding the lived experience of patients like my sons was the change we needed in our community. She made sure Spark's approach was all about us – our mindset, our needs, our priorities. Jamie's dedication to our community set a whole new standard that I hold everyone in this industry to. After our paths went separate ways following Luxturna's FDA approval, I didn't see Jamie for ages. But then, this week at the World Orphan Drug Congress in Boston, there she was, across the room. It was like a movie scene: Long lost friends, shocked to see each other again, our wide eyes of shock followed by huge smiles as we made our way across a crowded convention floor toward each other! What a moment! Finding folks like Jamie, who not only get it but also make sure everyone on their team gets it too, is like striking gold. And it is rare in our rare disease journey to strike that gold. But there are folks stepping up to the plate and the following Jamie's lead. We are blessed. We need more. #RareDisease #PatientAdvocate #Advocacy #partnership #pharma #CLinicalResearch #CRB1 #PatientOrganization #relationships #IRD Curing Retinal Blindness Foundation (CRB1.org)

In this episode, Partner and Co-Chair of the Firm’s Health Care Practice Group Kyle Faget, and Partner Monica Chmielewski are joined by Jodi Akin, Founder and CEO of Hawthorne Effect. Hawthorne Effect has embraced the decentralized clinical trial (DCT) model and is dedicated to enriching the quality, experience, diversity, and access to clinical trials for patients, providers, and sponsors. They explore the newly released FDA Guidance on DCTs, and how Hawthorne Effect was positioned for this guidance and what steps it will take to adapt its practices. They also explore the unique opportunities afforded by conducting DCTs. #clinicaltrial #clinicalresearch #DCT #decentralizedclinicaltrial

With the present market for oncology drugs worth around USD 160bn and currently growing at a low-double-digit rate, we see potential for it to grow sustainably at above-GDP growth rates in the medium term

The success of a clinical trial depends on a skilled Global Study Manager, meticulously coordinating diverse stakeholders and navigating unforeseen challenges. Meet Estelle de Bary, our expert behind seamless clinical trial studies at #Aixial Group. Watch her video for more insights about her expertise! #AixialGroup #CRO #GlobalStudyManager #ClinicalOperations

Are you aware Santa can pay your diagnostics bills? Watch to the end to find out HOW. #hmo #santa #santaclaus #yuletide #healthpartners #diagnosticservices #labsinajah #labsnearme #diagnosticcentre #healthcareinlagos #healthcareinportharcourt #wellmedhealthcare